US 12,129,298 B2
Compositions including CD3 antigen binding fragments and uses thereof
Thomas Spreter Von Kreudenstein, Wiesbaden (DE)
Assigned to Daiichi Sankyo Company, Limited, Tokyo (JP)
Appl. No. 17/254,105
Filed by Daiichi Sankyo Company, Limited, Tokyo (JP)
PCT Filed Jun. 20, 2019, PCT No. PCT/IB2019/055228
§ 371(c)(1), (2) Date Dec. 18, 2020,
PCT Pub. No. WO2019/244107, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/687,967, filed on Jun. 21, 2018.
Prior Publication US 2021/0277118 A1, Sep. 9, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/94 (2013.01)] 26 Claims
 
1. An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein:
(a) the VH comprises a VH-CDR1 sequence of GVTFNYYG (SEQ ID NO: 3), a VH-CDR2 sequence selected from the group consisting of ITRSGGRI (SEQ ID NO: 5) and ITSSGGRI (SEQ ID NO: 14), and a VH-CDR3 sequence of TLDGREGWVAY (SEQ ID NO: 156); and
(b) the VL comprises a VL-CDR1 sequence of: TGNIGSNY (SEQ ID NO: 7), a VL-CDR2 sequence of RND (SEQ ID NO: 9), and a VL-CDR3 sequence of: QSYSSGFI (SEQ ID NO: 8); wherein the VH and VL are connected via an amino acid linker comprising the sequence (GGGGS)3 (SEQ ID NO: 224).